Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL10743699 | 1.00 | FFAR3 (0.58) | — | |
| Acetic Acid SCHEMBL275637 | 0.96 | FFAR3 (0.54) | — | |
| Acetic Acid SCHEMBL282406 | 0.96 | — | — | |
| Acetic Acid SCHEMBL8785366 | 0.96 | FFAR3 (0.64) | — | |
| Acetic Acid SCHEMBL28343178 | 0.96 | FFAR3 (0.64) | — | |
| Acetic Acid SCHEMBL2706810 | 0.96 | FFAR3 (0.64) | — | |
| Acetic Acid SCHEMBL5035361 | 0.96 | — | — | |
| Acetic Acid SCHEMBL890387 | 0.92 | FFAR3 (0.58) | — | |
| Acetic Acid SCHEMBL8842862 | 0.92 | — | — | |
| Acetic Acid SCHEMBL59820 | 0.92 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2814807-A1 | LINEAR PEPTIDE ANTIBIOTICS | RQX Pharmaceuticals, Inc. (US) | 2014-12-24 | — | — | EP | disclosed |
| WO-2013123456-A1 | LINEAR PEPTIDE ANTIBIOTICS | RQX PHARMACEUTICALS, INC. (US) | 2013-08-22 | — | — | WO | disclosed |
| EP-0514198-B1 | 1H-Imidazol-1-yl-methyl benzofuran derivatives with the imidazolyl moiety being substituted by a cycloalkyl group | GLAXO GROUP LTD (GB) | 1998-08-05 | — | — | EP | disclosed |
| US-5498722-A | HYPOTENSIVES | GLAXO GROUP (GB) | 1996-03-12 | — | — | US | disclosed |
| US-5389659-A | Hypotensive agents | GLAXO GROUP LIMITED (GB) | 1995-02-14 | — | — | US | disclosed |
| US-5374646-A | Treatment or prophylasix of hypertension and diseases associated with cognitive disorders | GLAXO GROUP LIMITED (GB) | 1994-12-20 | — | — | US | disclosed |
| US-5332831-A | Angiotensin antagonist | GLAXO GROUP LIMITED (GB) | 1994-07-26 | — | — | US | disclosed |
| US-5310927-A | Hypotensive agents; cognition activators; imidazolyl-2-aryl derivatives | GLAXO GROUP LIMITED (GB) | 1994-05-10 | — | — | US | disclosed |
| WO-1993005025-A1 | C-LINKED PYRAZOLE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 1993-03-18 | — | — | WO | disclosed |
| EP-0514193-A1 | N-linked imidazolyl-methyl benzofuran derivatives with antihypotensive activity | GLAXO GROUP LIMITED (GB) | 1992-11-19 | — | — | EP | disclosed |
| EP-0514192-A1 | Antihypertensive benzofuran derivatives, substituted by varied N-pyrimidinyl- or N-imidazolyl-methyl groups | GLAXO GROUP LIMITED (GB) | 1992-11-19 | — | — | EP | disclosed |
| EP-0514198-A1 | 1H-Imidazol-1-yl-methyl benzofuran derivatives with the imidazolyl moiety being substituted by a cycloalkyl group | GLAXO GROUP LIMITED (GB) | 1992-11-19 | — | — | EP | disclosed |
| WO-1992016552-A1 | 1-IMIDAZOLGEMETHYL BENZOFURAN DERIVATIVES AS INHIBITORS OF ANGIOTENSIN II ACTIVITY | GLAXO GROUP LIMITED (GB) | 1992-10-01 | — | — | WO | disclosed |
| EP-0505954-A1 | N-Imidazolylmethyl benzofuran derivatives as inhibitors of angiotensin II activity | GLAXO GROUP LIMITED (GB) | 1992-09-30 | — | — | EP | disclosed |
| EP-0446062-A1 | C-Linked pyrazole derivatives | GLAXO GROUP LIMITED (GB) | 1991-09-11 | — | — | EP | disclosed |